Tumor hypoxia: A key player in the regulation of stromal and anti-tumor responses;L'hypoxie tumorale

Medecine/Sciences

Volumn 30, Issue 4, 2014, Pages 422-428

  Hasmim, Meriem ^a   Messai, Yosra ^a   Noman, Muhammad Zaeem ^a   Chouaib, Salem ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL HYPOXIA; CELLULAR IMMUNITY; DRUG EFFECT; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; TUMOR MICROENVIRONMENT;

CELL HYPOXIA; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84900343418     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20143004017     Document Type: Article

References (52)

1. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat rev Cancer 2011; 12: 9-22.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
3. Noman MZ, Messai Y, Carre T, et al. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol 2011; 31: 357-377.
4. Chouaib S, Messai Y, Couve S, et al. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 2012; 3: 21.
5. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 2008; 20: 228-233.
6. Fionda C, Malgarini G, Soriani A, et al. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. J Immunol 2013; 190: 6662-6672.
7. Gray MJ, Zhang J, Ellis LM, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24: 3110-3120.
8. Carbajo-Pescador S, Ordonez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1alpha and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer 2013; 109: 83-91.
9. Baginska J, Viry E, Berchem G, et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci USA 2013; 110: 17450-17455.
10. Noman MZ, Buart S, Van Pelt J, et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182: 3510-3521.
11. Noh KH, Kim BW, Song KH, et al. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest 2012; 122: 4077-4093.
12. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009; 23: 2152-2165.
13. Imamura T, Kikuchi H, Herraiz MT, et al. HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer 2009; 124: 763-771.
14. Balsamo M, Manzini C, Pietra G, et al. Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol 2013; 43: 2756-2764.
15. Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2, its expression is modulated by androgen receptor, HIF-1alpha/HIF-1beta. Mol Cancer 2010; 9: 108.
16. Chan YC, Banerjee J, Choi SY, Sen CK. miR-210: the master hypoxamir. Microcirculation 2012; 19: 215-223.
17. Akalay I, Janji B, Hasmim M, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013; 73: 2418-2427.
18. Siemens DR, Hu N, Sheikhi AK, et al. Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 2008; 68: 4746-4753.
19. Yamada N, Yamanegi K, Ohyama H, et al. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1alpha-dependent manner. Int J Oncol 2012; 41: 2005-2012.
20. Perier A, Fregni G, Wittnebel S, et al. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene 2011; 30: 2622-2632.
21. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
22. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8: 618-631.
23. Doedens AL, Stockmann C, Rubinstein MP, et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 2010; 70: 7465-7475.
24. Leek RD, Talks KL, Pezzella F, et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 2002; 62: 1326-1329.
25. Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22: 238-244.
26. Corzo CA, Condamine T, Lu L, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-2453.
27. Sceneay J, Chow MT, Chen A, et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 2012; 72: 3906-3911.
28. Fan J, Cai H, Li Q, et al. The effects of ROS-mediating oxygen tension on human CD34(+)CD38(-) cells induced into mature dendritic cells. J Biotechnol 2012; 158: 104-111.
29. Jantsch J, Chakravortty D, Turza N, et al. Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol 2008; 180: 4697-4705.
30. Bosco MC, Pierobon D, Blengio F, et al. Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood 2011; 117: 2625-2639.
31. Blengio F, Raggi F, Pierobon D, et al. The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. Immunobiology 2013; 218: 76-89.
32. Olin MR, Andersen BM, Litterman AJ, et al. Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Res 2011; 71: 6583-6589.
33. Sun J, Zhang Y, Yang M, et al. Hypoxia induces T-cell apoptosis by inhibiting chemokine C receptor 7 expression: the role of adenosine receptor A(2). Cell Mol Immunol 2010; 7: 77-82.
34. Makino Y, Nakamura H, Ikeda E, et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol 2003; 171: 6534-6540.
35. Larbi A, Zelba H, Goldeck D, Pawelec G. Induction of HIF-1alpha and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. J Leukoc Biol 2010; 87: 265-273.
36. Caldwell CC, Kojima H, Lukashev D, et al. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 2001; 167: 6140-6149.
37. Lukashev D, Klebanov B, Kojima H, et al. Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol 2006; 177: 4962-4965.
38. Clambey ET, McNamee EN, Westrich JA, et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 2012; 109: E2784-E2793.
39. Dang EV, Barbi J, Yang HY, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011; 146: 772-784.
40. Winn HR, Rubio R, Berne RM. Brain adenosine concentration during hypoxia in rats. Am J Physiol 1981; 241: H235-H242.
41. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006; 103: 13132-13137.
42. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-230.
43. Sarkar S, Germeraad WT, Rouschop KM, et al. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One 2013; 8: e64835.
44. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
45. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
46. Provot S. Contrôle de la croissance et de la dissémination tumorales par le microenvironnement: certitudes et hypothèses émergentes. Med Sci (Paris) 2014; 30: 366-371.
47. Buache E, Rio MC. Le stroma tumoral, un terreau fertile pour la cellule cancéreuse. Med Sci (Paris) 2014; 30: 385-390.
48. Albrengues J, Meneguzzi G, Gaggioli C. L'invasion des cellules tumorales: quand les fibroblastes s'en mêlent. Med Sci (Paris) 2014; 30: 391-397.
49. Hubert S, Abastado JP. Les étapes précoces du processus métastatique. Med Sci (Paris) 2014; 30: 378-384.
50. Bruchard M, Ghiringhelli F. Micro-environnement tumoral: cellules régulatrices et cytokines immunosuppressives. Med Sci (Paris) 2014; 30: 429-435.
51. Galon J, Bindea G, Mlecnik B, et al. Microenvironnement immunitaire et cancer: intérêt de l'immunoscore pour prédire l'évolution clinique. Med Sci (Paris) 2014; 30: 439-444.
52. Tartour E, Sandoval F, Bonnefoy JY, Fridman WH. Cancer immunotherapy: recent breakthroughs and perspectives. Med Sci (Paris) 2011; 27: 833-841.